Mesenchymal stem cell (MSC) therapy has recently been investigated as a potential treatment for cutaneous radiation burns. We tested the hypothesis that injection of local gingival fibroblasts (GFs) would promote healing of radiation burn lesions and compared results with those for MSC transplantation. Human clinical-grade GFs or bone marrow-derived MSCs were intradermally injected into mice 21 days after local leg irradiation. Immunostaining and real-time PCR analysis were used to assess the effects of each treatment on extracellular matrix remodeling and inflammation in skin on days 28 and 50 postirradiation. GFs induced the early development of thick, fully regenerated epidermis, skin appendages, and hair follicles, earlier than MSCs did. The acceleration of wound healing by GFs involved rearrangement of the deposited collagen, modification of the Col/MMP/TIMP balance, and modulation of the expression and localization of tenascin-C and of the expression of growth factors (VEGF, EGF, and FGF7). As MSC treatment did, GF injection decreased the irradiation-induced inflammatory response and switched the differentiation of macrophages toward an M2-like phenotype, characterized by CD163\(^+\) macrophage infiltration and strong expression of arginase-1. These findings indicate that GFs are an attractive target for regenerative medicine, for easier to collect, can grow in culture, and promote cutaneous wound healing in irradiation burn lesions.

Introduction

Severe local radiation burns from radiological or nuclear incident cause successive but unpredictable inflammatory waves that lead to the horizontal and vertical extension of the necrotic process [1]. The acute response develops over the first few days to weeks after irradiation and is characterized by the early onset of erythema and alopecia, followed soon after by necrosis and ulceration of both cutaneous and subcutaneous tissue [2]. Although several strategies (including surgical procedures) have been used to treat severe radiation-induced skin damage used with some success [2], none has proven entirely satisfactory.

The idea of using stem cell injections to reduce normal tissue injury is not new [3]. More recent studies of wound healing have focused on mesenchymal stem cells (MSCs)—nonhematopoietic, adherent fibroblast-like cells with intrinsic capacity for self-renewal and differentiation—as a possible cell population within the bone marrow that might contribute to cutaneous repair, particularly in radiation burns [4–11]. Wound healing was orchestrated by several temporal processes including hemostasis, inflammation, granulation tissue formation, reepithelialization, and remodeling [12] and was regulated by local production of such growth factors as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor (TGF-β1), and different vascular endothelial growth factors (VEGF). The resulting effect provided cell proliferation, control of the extracellular matrix (ECM) deposition, and angiogenesis process. In addition to the acceleration of wound closure, the MSCs treatment strongly enhances the scar quality, which was associated to a greater quantity of collagen within the healed tissue increasing the tensile strength [13]. These cells’ synthesis of larger amounts of collagen and growth factors, than native dermal fibroblasts, proves their therapeutic efficiency in cutaneous repair [14]. Together, MSC differentiation helps to regenerate damaged tissue, while...
their paracrine signaling accelerates reepithelialization and fibroproliferation during wound repair [15].

Some points must be considered in planning and assessing MSC-based wound healing therapy. One is that the cells traditionally used are located in bone marrow stroma. The patients’ age must also be considered, because stem cell functionality decreases in older patients [16]. Moreover, aspiration of bone marrow from the iliac crest is an invasive procedure. Finally, preparation of MSCs varies between studies [17].

One of the different MSC sources thus far investigated, gingival tissue, has drawn increased interest recently, mainly because it can be obtained from donors non-invasively. Gingival fibroblast (GF) culture, in which ~3% of cells form colonies, expresses membrane markers similar to those of bone marrow-derived MSCs [18,19] and has, like them, immunomodulatory functions and the potential for multilineage differentiation [20,21]. The efficacy of GFs in wound healing was recently shown in a full-thickness skin defect [22]. Still more recently, a suspension of GFs in contact with the arterial wall not only stabilized aneurysms but also caused their regression, with a functional elastin network restored and persisting after 3 months [23]. GFs can be harvested easily and less invasively from gingival mucosa than MSCs obtained from bone marrow. In this study, we investigated the ability of GFs to promote the healing of cutaneous radiation burns and compared it to the reference MSC treatment [5,9].

Materials and Methods

Animals and treatment procedures

NOD-LtSz-scid/scid (NOD/SCID) mice, from breeding pairs originally purchased from Jackson Laboratory, were bred in our pathogen-free unit and maintained in sterile micro-isolator cages with unlimited access to food and drinking water. All experiments and procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published in accordance with the French regulations for animal experiments (Ministry of Agriculture Order No. B92-032-01, 2006) and European Directive 86/609/EEC, and they were approved by the Ethics Committee of the Institute for Radiological Protection and Nuclear Safety.

This study used 60 eight-week-old pathogen-free NOD-SCID mice, divided into eight groups, two not irradiated. Mice were anesthetized with ketamine and xylazine and irradiated at the right hind leg at a dose of 30 Gy (dose rate 1 Gy/min) with a 60Co source. Lead shielding was used to protect the rest of the body from irradiation. Physical dosimetry by thermoluminescent dosimeters indicated that the expected dose was delivered to the right leg and that other parts of the body remained unexposed. Radiation-induced lesions were clearly established 21 days after irradiation, the time chosen as the starting point for cell treatment. Two groups received irradiation only, two groups were irradiated and received hMSC (2.5 × 10^6) treatment, and two groups were irradiated and received hGF (1.5 × 10^6). On day 21 after irradiation, under anesthesia, the cell treatments were locally injected into several sites (shin and subcutaneous skeletal muscle) of the irradiated leg. One group with each treatment condition (sham-irradiated, irradiated-untreated, or irradiated and treated with hMSC or GF) was humanely killed on day 28 and the other group on day 50 after irradiation (7 and 29 days after cell treatment).

Isolation and expansion of human MSCs and GFs

Human mesenchymal stem cells. Human bone marrow-derived MSCs were obtained with informed consent from various patients undergoing routine total hip replacement surgery at the Percy Hospital (Clamart, France). The Ethics Committee of the Service de Santé des Armées (Army Health Department, Ministry of Defense) approved this research on human material. As previously reported [9], bone marrow mononuclear cells (BMMNCs) were isolated from the supernatant of spongy bone fragments, plated at a density of 100 × 10^3 cells/cm², and cultured at 37°C in 95% air and 5% CO2 in alpha-minimum essential medium (α-MEM) (Macopharma) with 10 µg/mL ciprofloxacin (Ciflox 400 mg/200 mL; Bayer Pharma) and 8% human platelet lysate as a source of growth factors. After 3–4 days, nonadherent cells were removed and cultures were again fed with fresh medium. Thereafter, cultures were fed at 3- to 4-day intervals. On days 16–21 after the start of the culture, adherent MSCs reached confluence. They were detached with 1× trypsin-EDTA (Life Technologies, www.lifetechnologies.com) and replated at 4,000 cells/cm². Expanded MSCs were validated for their standard phenotypic markers by flow cytometry (CD45⁻/CD105⁺/CD73⁺/CD90⁻), their colony-forming unit-fibroblast potential (CFU-F assay), and their multilineage differentiation potential (osteogenic, adipogenic, and chondrogenic).

Human gingival fibroblasts. Gingival tissue samples were obtained from healthy patients undergoing extraction of the third molar or orthodontic procedures. The study was approved by the local ethics committee (Comité de Protection des Personnes (CPP) “Ile de France II” (May 11, 2012), IRB registration: 00001072) and all subjects gave written informed consent. As previously reported [19,21], primary explant cultures were established in Dulbecco’s modified Eagle’s medium (DMEM) containing 5% human platelet lysate, penicillin (100 µg/mL), streptomycin (100 µg/mL), and amphotericin B (2 ng/mL) over 2-week periods. Monolayer cultures were maintained in 5% CO2 and the cell culture medium was changed every 72 h. After 2 weeks, the GFs were trypsinized and single-cell suspensions were seeded at very low concentrations (≤100 cells/cm²); medium, DMEM 10% of FBS with 50 mg/mL of ascorbic acid after verification of the absence of cell aggregates to avoid false positives. After 14 days of culture, the CFU-F were counted; only aggregates of >50 cells were considered colonies. The CFU-F were then transferred, pooled in a single 25-cm² flask, and cultivated in DMEM 10% supplemented with 50 mg/mL of ascorbic acid. Expanded GFs were tested to check that they expressed the same markers as the BM-MSCs (CD29⁺/CD44⁺/CD73⁺/CD105⁻) and for their multilineage differentiation potential (osteogenic, adipogenic, and chondrogenic).

Histology and immunohistochemistry

Freshly isolated tissue was fixed in 4% paraformaldehyde and embedded in paraffin. Sections 5 μm in thickness were dewaxed and hydrated; endogenous peroxidase was blocked.
with 3% hydrogen peroxide for 10 min; and nonspecific binding was blocked with a protein blocker (DakoCyto- 
mation, www.dakocytomation.com). Masson trichrome staining by the standard method was used to assess collagen 
deposition. After antigen retrieval, sections were incubated in primary antibodies against α-SMA, CTGF, tenasin-C, 
F4/80 (AbCam), and CD163 (Antibodies-Online.com, www .antibodies-online.com). The EnVision™ System-horseradish 
peroxidase (HRP) (DakoCyto) was used as the secondary 
reagent for all immunostaining sections. The color reaction 
was developed with the NovaRED™ kit (Vector 
Laboratories, www.vectorlabs.com) and counterstained with 
Mayer’s hemalun.

Detection of hMSC and hGF in irradiated tissue

A real-time PCR-based assay was used to detect the 
presence of human cells in the tissue of mice receiving 
hMSC or hGF infusions. Genomic DNA was extracted from 
skin samples by the DNEasy method (Qiagen, www.qiagen 
.com); a 1-μg aliquot of total DNA was used in each PCR re-
action, all run on an ABI Prism 7900 sequence detection system. 
System genomic DNA from the human cells was amplified 
with primers directed against GAPDH (Hs00894322_cn; 
Life Technologies) and HPRT (Hs05632001_cn; Life 
Technologies). A genomic DNA sequence located in the noncoding 
region of the beta-2 microglobulin locus (Mm00047666_cn; 
Life technol-
gies). A genomic DNA sequence located in the noncoding 
region of the beta-2 microglobulin locus (Mm00047666_cn; 
Life technologies) was used as an internal control. All PCR 
experiments were performed with appropriate controls, in-
cluding absence of HuGAPDH and HuHPRT in mice not 
treated with human cells.

Real-time PCR analysis

Total RNA was extracted from cultured hGF, hMSC, and 
the anus, rectum, and colon with the RNeasy Mini kit (Qiagen), and cDNA prepared with the SuperScript RT 
Reagent Kit (Life Technologies). Real-time PCR was per-
formed on an ABI Prism 7900 sequence detection system. 
SYBR chemistry (Life Technologies) was used to amplify 
PCTTCTTCTACCTTCC-3‘; R:5’-ACTCATAAGGACTGAC 
CAAGGTGG-3‘); VEGF (F:5’-CATCTTCAAGCCGGCTCTGTTG-3‘; R:5’-CT 
CAAGGGCTTATCGTTACA-3‘); CD68 (F:5’-TTGGGAA 
CTACACACGGGCC-3‘; R:5’-CAGGTTGGAATTTGGG 
CTTG-3‘); MCP1 (F:5’-CTCTGGGCTGTCACCTA-3‘; R:5’-CCACTCATTGGGAATGGAGCCTA-3‘; and iNOS (F:5’- 
CATGGGACTGCTGGTGTC-3‘; R:5’-CAGCTGCTGGCT 
GTACACACT-3‘). All other TaqMan primers and probes 
came from Life Technologies. Data were analyzed by the 2−ΔΔCt 
method, with normalization to the Ct of the housekeeping 
gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase).

Enzyme-linked immunosorbent assay

Tissues were homogenized in a cold RIPA buffer (Sigma) 
containing a standard protease-inhibitor cocktail. The sam-
ple were then centrifuged at 10,000 g for 10 min, and the 
supernatants stored at −20°C for later measurement. Human 
and mouse TIMP1 concentrations were determined by spe-
cific enzyme-linked immunosorbent assay (ELISA) ac-
cording to the manufacturer’s instructions (R&D Systems). 
Any cross-reaction between human and mouse was detected.

Statistics

Data are expressed as means ± SEM. One-way analysis of 
variance was used followed by a Bonferroni post-test to 
determine the significance of differences. P values less than 
0.05 were considered statistically significant.

Results

Gene expression of transplanted MSCs and GFs

RT-PCR analysis was performed to investigate the relative 
mRNA expression levels of selected growth factors, 
cytokines and chemokines associated with inflammation, 
neovascularization and reepithelialization, and/or remodeling 
injected in BM-MSCs and GF. As shown in Fig. 1 and 
compared to mRNA expression levels of injected MSC, GF 
repressed inflammatory cytokine/chemokines (IL-1β, 
CC15, and CXCL2) and overexpressed anti-inflammatory cytokine 
IL-1Ra (13-fold), angiogenesis factors (angiotensinogen, 
11.8-fold; endothelin 1, 7-fold; thrombomodulin, 5.5-fold; 
VWF, 3.5-fold), and remodeling factors (fibroblast activation 
protein a, 3-fold; S100A4, 4.3-fold; TGF-β2, 9.5-fold; 
membrane metallo endopeptidase, 10-fold and Noggin, 
26.5-fold).

Persistence of transplanted MSCs and GFs 
in irradiated skin

Real-time PCR was used to detect genomic DNA (di-
rected against the GAPDH and HPRT of human MSCs or 
GFs) from irradiated mouse skin samples collected 7 and 
29 days after cell injection (days 28 and 50 after irradiation). At 
7 days, human-derived cells were detectable by PCR in 50% 
of mouse skins after MSC treatment and in 60% after GF 
treatment; the corresponding results at 29 days were 40% 
and 60%, respectively. After determining that human 
TIMP1 did not cross-react with that of mice (no hTIMP1 
protein was detected in nonirradiated or irradiated-untreated 
mice), we immunoassayed hTIMP1 in the skins of treated 
mice and found that its concentration decreased over time 
after MSC treatment, but remained high at 29 days after GF 
treatment (Table 1). Together, these results showed that GFs 
persisted longer in tissue than MSCs.

Effects of MSCs and GFs on collagen content 
in irradiated skin

The ability of MSCs and GFs to regenerate skin repair 
was evaluated in cutaneous radiation lesions after subcuta-
aneous cell transplantation. Macroscopic images and histo-
logic assessment of tissue sections stained with Masson’s 
trichrome dyes revealed cutaneous ulceration and failed 
epithelialization on day 28 after irradiation in the irradiated-
untreated group (Fig. 2A, B). Although the wound site 
was covered on day 50, hyperplasia of the epidermis was ob-
served, marked by extensive hyperkeratosis, atrophy of the 
dermal appendages, a drastic reduction in the number of hair 
follicles and sebaceous glands, and atrophy of those that 
remained (Fig. 2B). On day 28 (7 days after transplantation), 
the GF-treated mice had notably less epidermal hyperplasia,
restored dermal appendages, and more hair follicles. The MSC treatment induced the same effect, but at a later point in time, on day 50 (29 days after the graft), although the anagen phase occurs earlier than with GF treatment. Analysis of the overall collagen content showed a high density of dermal collagen fibers with unidirectional alignment in the control irradiated skin on days 28 and 50 (Fig. 2C). The restoration of normal fiber density and their multidirectional alignment (remodeling), resembling nonirradiated skin, was visible on day 28 in the GF-treated skin but not until day 50 in the MSC-treated skin. Histomorphometric analysis showed that the earliest signs of tissue regeneration appeared earlier in GFs than MSCs.

To evaluate the molecular effects of MSCs and GFs on matrix production, we used real-time PCR to measure expression of collagen 1 and 3, which constitute the bulk of the scar tissue ECM. Irradiation significantly increased the collagen 3 expression observed on days 28 and 50 (two and three-fold respectively, \( P < 0.01 \)), compared with nonirradiated skin (Fig. 2D). This overexpression continued on day 28 after both MSC (\( \times 4.8\)-fold) and GF (\( \times 3\)-fold) treatment but returned to normal by day 50. Collagen 1 expression, on the contrary, was unaffected by irradiation but significantly increased after MSC and GF treatment on day 28 (2.6 and 3-fold respectively, \( P < 0.01 \)), compared with nonirradiated and irradiated skin. The resulting ratio of collagen I/III is an indicator of tissue quality, which was poor (0.2 on day 28 and 0.4 on day 50) in irradiated-untreated compared to nonirradiated skin. For GF-treated skin, this ratio had returned to normal levels by day 28, and for MSC-treated skin, by day 50.

MSCs and GFs modified ECM-related gene expression

MMPs degrade collagens, and TIMPs inhibit MMP activity. For this reason, we performed real-time PCR to examine the expression of several MMPs and TIMP1. MMP2 expression was transiently increased on day 28 in irradiated-untreated mice (Fig. 3A), but normalized by that time in GF-treated mice. Irradiated-untreated mice strongly overexpressed both MMP3 and MMP13 on both day 28 and 50 postirradiation; their levels were also elevated at both time points in MSC- and GF-treated mice. Similarly, TIMP1 expression was strongly overexpressed on day 28 in the skin of irradiated mice, although transiently (Fig. 3B). This enhanced TIMP1 expression persisted in MSC- and GF-treated mice, on both day 28 and 50. The ELISA assay confirmed this finding at the protein level.

Because collagen synthesis/degradation depends on the dynamic interactions of these proteins, their relation was assessed by the collagen-to-MMP-to-TIMP ratio, a method of defining net collagen deposition based on real-time PCR results [24]: the collagen mRNA value is divided by the fold change value for the relevant MMPs and TIMPs (Fig. 3C). The collagen/MMPP:TIMP ratio is 1 for nonirradiated skin, which is assumed to have no net collagen deposition or

---

**FIG. 1.** mRNA expression levels of GF compared to BM-MSCs before transplantation. Real-time PCR assays were performed to measure mRNA levels of inflammatory, neovascularization, and remodeling factors in GF compared to BM-MSCs. The fold changes were generated by comparing cultured hGF (histogramme) with hMSCs (basal line to 1). GAPDH was quantified as an internal control. MSC, mesenchymal stem cell; GF, gingival fibroblast; Irr, irradiation.

**Table 1. Persistence of Transplanted Mesenchymal Stem Cells or Gingival Fibroblast in Irradiated Skin**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Irr</th>
<th>Irr + MSC</th>
<th>Irr + GF</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of mouse with human-derived cells detected</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D28</td>
<td>ND</td>
<td>ND</td>
<td>50%</td>
<td>60%</td>
</tr>
<tr>
<td>D50</td>
<td>ND</td>
<td>ND</td>
<td>40%</td>
<td>60%</td>
</tr>
<tr>
<td>Human TIMP in mouse tissue (ng/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D28</td>
<td>ND</td>
<td>ND</td>
<td>78.4 ± 18.3</td>
<td>153.5 ± 46.0</td>
</tr>
<tr>
<td>D50</td>
<td>ND</td>
<td>ND</td>
<td>29.5 ± 13.0</td>
<td>83.6 ± 26.6</td>
</tr>
</tbody>
</table>

GF, gingival fibroblast; Irr, irradiation; MSC, mesenchymal stem cell; ND, not detected.
degradation. For collagen 1 and 3, the net collagen/MMPP:TIMP ratio was elevated after MSC and GF treatment, and significantly higher in GF-treated compared to irradiated-untreated mice on day 28.

MSCs and GFs modulated the expression of ECM components

Tenascin-C is regarded as a marker for immature ECM in the earlier phase of tissue repair and plays an important role in myofibroblast recruitment [25]: the dramatic change in its expression demonstrates its key role in the wound healing process. Real-time PCR showed significant overexpression of tenascin-C in irradiated-untreated skin on both days 28 and 50 (P < 0.001). MSC treatment did not modify the irradiation-induced enhancement of tenascin-C expression, but its level on day 28 was significantly lower in GF-treated mice (Fig. 4A). In nonirradiated skin, immunostaining detected tenascin-C mainly in the nascent hair follicle and bulge stem cells (Fig. 4B). On day 28 in irradiated-untreated mouse skin, tenascin-C staining was marked at the dermal–epidermal junction and around the residual hair follicles. At this early point in MSC-treated skin, the tenascin-C staining showed a continuous distribution in the basement membrane of the dermal–epidermal junction and in the dermis, mostly close to hair follicles. GF-treated skin, on the other hand, showed discontinuous tenascin-C staining in the dermal–epidermal junction and in part around the hair follicles. On day 50, the irradiated-untreated skin showed intense tenascin-C staining at the dermal–epidermal junction and in the adjacent dermis, where collagen fibers were organized parallel to the wound surface. At this point, the detection of tenascin-C staining in the MSC-treated skin was discontinuous at the dermal–epidermal junction and in the nascent hair follicles and bulge stem cells, while that in GF-treated skin was similar to that in the skin of nonirradiated mice.

In view of previous reports that tenascin-C promotes recruitment of myofibroblasts [26], we assessed the localization of α-smooth muscle actin (SMA) by immunostaining. In the dermis of nonirradiated skin, α-SMA was expressed close to the perifollicular dermal sheath area and vascular wall (Fig. 4C). Irradiated mouse skin (assessed on days 28 and 50 after irradiation) showed stronger α-SMA staining in the dermis. In mice treated with MSCs, α-SMA-positive cells were located near the vascular wall on day 28. In GF-treated mice, as in the nonirradiated mice, α-SMA was
expressed near the perifollicular dermal sheath by day 28, and in MSC-treated mice by day 50.

Expression of wound healing-related factors in wounded tissue

TGF-β1 and CTGF, working synergistically, and PAI-1 play active roles in fibroblast-to-myofibroblast activation and matrix deposition, in addition to negative roles in wound reepithelialization. For that reason, we used real-time PCR to analyze their expression in irradiated-untreated and irradiated MSC- and GF-treated groups on days 28 and 50 after irradiation, compared with control groups. Results are expressed as mean±SEM. P values were calculated by ANOVA with Bonferroni correction. *P<0.05; **P<0.01; ***P<0.001 compared with nonirradiated controls; #P<0.05; ##P<0.01; ###P<0.001 compared with irradiated-untreated controls. ECM, extracellular matrix.

FIG. 3. MSC or GF treatment influences ECM remodeling. (A) Real-time expression of MMP-2, MMP-3, and MMP-13. (B) TIMP-1 mRNA and protein expression. Levels of mRNA are expressed relative to control mice and normalized to GAPDH. Protein was measured in skin by ELISA test. (C) Collagen-to-MMP-to-TIMP ratio: relative expression of MMP was calculated by determining the fold change of MMP mRNA levels relative to its relevant inhibitor TIMP in irradiated-untreated and irradiated MSC- and GF-treated groups on days 28 and 50 after irradiation, compared with control groups. Results are expressed as mean±SEM. P values were calculated by ANOVA with Bonferroni correction. *P<0.05; **P<0.01; ***P<0.001 compared with nonirradiated controls; #P<0.05; ##P<0.01; ###P<0.001 compared with irradiated-untreated controls. ECM, extracellular matrix.

expression of TGF-β1 had normalized at that point in GF-treated skin and that of CTGF in both MSC- and GF-treated skin. Similarly, both treatments reduced the increased PAI-1 expression observed in irradiated-untreated skin—a 3-fold increase on day 28 and 23-fold on day 50, compared with nonirradiated skin. Immunostaining confirmed that both MSC and GF treatment substantially reduced the intensity of CTGF staining observed in the dermis on day 50 in irradiated-untreated skin near the perifollicular dermal sheath area (Fig. 5B).

Other growth factors, such as VEGF, FGF7, and EGF, have been implicated in wound repair [27]. Consistent with these reports, VEGF expression was significantly enhanced on day 28 by GF treatment and on day 50 by MSC treatment, compared with irradiated-untreated skin (Fig. 6A). Moreover, endothelial nitric oxide synthase expression also tended to return to normal levels by day 28 in GF-treated skin. EGF and FGF7 expression was significantly modified
FIG. 4. Expression of ECM components. (A) Real-time PCR of tenascin-C in nonirradiated control skin, irradiated-untreated skin, and MSC- or GF-treated skin on days 28 and 50 after irradiation. Data are reported relative to control mice and normalized to GAPDH. (B) Representative immunohistochemical staining with the primary anti-tenascin-C antibody and (C) the primary α-SMA antibody. Inserts were amplified local areas from the same images. Original magnification ×20. Results are expressed as mean ± SEM. *P values were calculated by ANOVA with Bonferroni correction, **P < 0.001; compared with nonirradiated controls; *P < 0.01 compared with irradiated-untreated controls.

FIG. 5. Expression of wound healing-related factors. (A) Real-time PCR of TGF-β, CTGF, and PAI-1 in nonirradiated control skin, in irradiated-untreated skin, and in MSC- or GF-treated skin on days 28 and 50 after irradiation. Data are reported relative to control mice and normalized to GAPDH. (B) Representative immunohistochemical staining with the primary CTGF antibody. Inserts were amplified local areas from the same images. Original magnification ×20. Results are expressed as mean ± SEM. *P values were calculated by ANOVA with Bonferroni correction, *P < 0.05; **P < 0.01 compared with nonirradiated controls; *P < 0.05; ***P < 0.01; ****P < 0.001 compared with irradiated-untreated controls.
in irradiated-untreated skin (Fig. 6B). Only GF treatment normalized EGF expression ($P < 0.01$ compared to irradiated skin). Although FGF7 was upregulated on day 28 in mice with GF transplants, the mRNA level returned to normal only on day 50 after irradiation in MSC-treated skin.

**Macrophage recruitment induced by MSC and GF treatment promotes alternative activation**

Previous studies have established that macrophages enter sites of tissue injury, where they facilitate angiogenesis and promote wound repair [28]. We used real-time PCR to evaluate the local anti-inflammatory effect of MSC and GF treatment (Fig. 7A). The overexpression of IL-6 and IL-1β induced by irradiation was significantly downregulated after one week of MSC or GF treatment (D28). ELISA assays also confirmed the decrease in IL-1β at the protein level in mice treated with MSCs and GFs on both days 28 and 50 postirradiation.

Compared with nonirradiated skin, irradiated-untreated skin in addition to MSC- and GF-treated skin had higher numbers of cells that stained for the macrophage marker F4/80 (Fig. 7B). Real-time PCR confirmed the increase in IL-1β at the protein level in mice treated with MSCs and GFs on both days 28 and 50 postirradiation.

To determine whether the macrophages present after MSC or GF transplantation phenotypically differed from those present after irradiation, we used real-time PCR to assess the expression of inducible nitric oxide synthase (iNOS) (marker of the M1 proinflammatory macrophages) and Arginase-1 (Arg-1, expressed by the M2 alternatively activated macrophages). As Fig. 7D shows, inducible nitric oxide synthase expression increased by a factor of 90 ($P < 0.001$) on day 28 and of 8 ($P < 0.05$) on day 50. Arg-1 expression did not differ in irradiated compared to nonirradiated skin. MSC or GF treatment substantially reduced iNOS expression at both time points, while Arg-1 expression on days 28 and 50 increased compared with irradiated-untreated skin. Analysis of the ratio of iNOS/Arg-1 mRNA levels, an indicator of the M1/M2 activity balance [29], showed that irradiation skewed this ratio toward iNOS expression. After either MSC or GF treatment, this ratio markedly decreased and skewed back toward Arg-1 expression, compared with irradiated-untreated skin. Immunostaining of CD163+ cells showed that the number of M2 macrophages increased after MSC or GF administration, compared with nonirradiated and irradiated-untreated skin (Fig. 7E).

**Discussion**

The clinical benefits of local MSC grafts in promoting healing of radiation burn lesions have been demonstrated in several different preclinical models [7,8] and in humans [5,9]. The healing of skin wounds involves complex interactions between different cell types, including fibroblasts and epithelial, endothelial, and inflammatory cells, ECM molecules, growth factors, and cytokines [4]. We investigated the performance of GF tissue grafts in wound healing and compared it to the reference MSC therapy, using a local irradiation model, human bone marrow-derived MSCs, and GFs, expanded according to a clinical-grade protocol.

GFs express mesenchymal cell surface markers and are capable of multiple mesodermal differentiations. Interestingly, GFs injected near the lesion remained detectable for a longer time after grafting than did bone marrow-derived MSCs. This observation confirms a previous report in an aneurysm model where GFs remained detectable 3 months after cell therapy, although more than 90% of the injected MSCs disappeared in the first few days [23].

**FIG. 6.** Expression of growth factors implicated in wound repair. Real-time PCR of VEGF and eNOS (A) and EGF and FGF7 (B) in nonirradiated control skin, in irradiated-untreated skin, and in MSC- or GF-treated skin on days 28 and 50 after irradiation. Data are reported relative to control mice and normalized to GAPDH. Results are expressed as mean±SEM. $P$ values were calculated by ANOVA with Bonferroni correction, $*P < 0.05$; $**P < 0.01$; $***P < 0.001$ compared with nonirradiated controls; $#P < 0.05$; $##P < 0.01$; $###P < 0.001$ compared with irradiated-untreated controls. eNOS, endothelial nitric oxide synthase.
A specific series of events occurs during the closure and repair of wounds caused by radiation. These events include an inflammatory step due to the monocytes/macrophages infiltration, secretion of cytokines/chemokines, cell migration, differentiation of fibroblasts to myofibroblasts, and synthesis/accumulation of collagen and other ECM proteins in the matrix. The magnitude of ECM protein accumulation is tightly controlled by the balance between the synthesis of ECM and its degradation.

The histological changes we observed in our murine model were typical of irradiated skin (epidermal atrophy, hyperkeratosis, atrophy of dermal appendages, hair follicle sterilization, and unidirectional alignment of collagen fibers) [30]. Histological evaluation of the wound in GF-treated skin after only one week of treatment revealed early development of thick, fully regenerated epidermis, skin appendages, and the presence of hair follicles. In MSC-treated skin, in contrast, appendages had not yet developed at this point, and hair follicles were present in the earliest anagen state; epidermal thickness and appendages were nonetheless similar to that of nonirradiated skin only 3 weeks after treatment. The arrangement of the deposited collagen in different directions, in a network similar to that of control skin, took place later in MSC-treated skin than in GF-treated skin.

Wound maturity is related to the initial deposition of thin collagen 3, with type 1 collagen prevalent only later [31]. Type 3 collagen are abundant in young granulation and scar tissue while the type 1 collagen is few present in this early phase of healing. The ratio of type 1 to type 3 collagen is thus low. Although collagen 1 overexpression was observed as early as day 28 postirradiation in both MSC and GF treatment normalization of the ratio was observed later in MSC treatment; this finding indicates delayed healing compared to GF treatment. As previously reported, though
type 1 and type 3 collagen fibers coexist within individual fibrils, their relative ratios play an important role in the regulation of fibrillogenesis and in the determination of the final fibular diameter and bundle architecture [32]. The mature type 1 collagen is responsible for mechanical stability, whereas the type 3 collagen that forms thin fibers can be regarded as immature collagen of the early wound healing process. MMPs and TIMPs perform this stage of wound repair-remodeling. In our study, the maximum collagen-to-MMP-to-TIMP ratios—on day 28 in GF-treated skin and on day 50 in MSC-treated skin—confirm the peak time of collagen production.

Tenascin-C, which is transiently upregulated during the proliferative phase of healing and is predominantly produced by fibroblasts, virtually disappears in mature tissue [25]. In our study, irradiation induced strong tenasin-C expression localized at the dermal–epidermal junction. In the mice treated by MSCs and GFs, real-time PCR analysis showed that tenasin-C expression remained high compared to nonirradiated mice, but immunostaining revealed discontinuous localization in the dermal–epidermal junction, mostly close to hair follicles. Some reports indicate that tenasin-C is present throughout the matrix of granulation tissue, filling full-thickness wounds, but it is not detectable in the scar after the completion of wound contraction [33]. Tenasin-C may also interact with the contractile properties of myofibroblasts to influence wound contraction. In our study, α-SMA immunostaining indicated an increase of myofibroblasts in the dermis of irradiated-untreated skin. In MSC- or GF-treated skin, on the other hand, myofibroblast immunostaining decreased and was restricted to hair follicles. Our findings are thus in line with the report of tenasin-C involvement in myofibroblast recruitment [26]; the presence of tenasin-C on day 50 postirradiation in our study signals immature tissue granulation and ongoing migration. MSC and GF treatment thus appear to have accelerated the wound healing process, with tenasin-C rapidly disappearing after wound contraction was complete [33]. The α-SMA+ myofibroblasts are present in the early stage of the wound, and they rapidly disappear when wound healing progresses [34]. An interesting recent study reports that whisker follicle stem cell niches contain tenasin-C and suggests that this glycoprotein might play a role in directing the migration and proliferation of these stem cells [35]. In our study, the presence of tenasin-C close to hair follicles may predict hair stem cell niche restoration by MSC and GF treatment.

It is generally accepted that the efficacy of MSC transplantation is associated with the immunomodulatory activity of these cells [36]. Similarly, GF cell therapy has recently been associated with a reduction in proinflammatory cytokines [23]. We have shown here a significant downregulation of IL-1β and IL-6 in irradiated mouse skin treated with MSCs and GFs. Although macrophages are the major source of proinflammatory cytokines, neither the CD68 mRNA level nor immunostaining showed a reduction in macrophage infiltration after either MSC or GF treatment. The possibility that treatment with bone marrow-derived MSCs enhances wound healing by increasing the recruitment of macrophages to the wound site has been evoked [37]. Recruited macrophages induce granulation tissue and myofibroblast differentiation during the early stage of the repair and are crucial for the stabilization of vascular structures and the transition of granulation tissue to scar tissue during intermediate stages of repair [28]. MSCs are involved in reprogramming macrophages to an M2 phenotype, through their IL-10 production; they thus enhance wound healing [38]. An important point demonstrated by Horton et al. is that the bone marrow-derived MSC infusion that slows or stops the progression of radiation-induced cutaneous fibrosis is associated with the presence of CD163+ macrophages [39].

Similarly, we have shown that MSC treatment switched the differentiation of macrophages to an M2-like phenotype: we observed specific M2 markers, including the expression of Arg-1, a key feature of M2, and the presence of CD163+ macrophages one week after treatment (day 28 after irradiation). We have shown for the first time that GF treatment also induces an M2 phenotype, just as MSC treatment does. Once recruited to the wound, M2 macrophages promoted angiogenesis, myofibroblast differentiation, and control of follicle size and thus led to the expression of VEGF and TGF-β1 [28,39]. Our data show that MSC and GF treatment increased VEGF expression and that this response occurred earlier in GF-treated skin than in MSC-treated skin.

Although M2 macrophages provide a source for VEGF [28], analysis of the MSC-conditioned medium indicated that MSC secretes many tissue repair mediators, including angiogenic proteins such as VEGFs and epithelial cell stimulatory proteins such as EGF and FGF7 [37]. Physiological levels of these growth factors are critical for ensuring wound healing [40]. Recently, Séguier et al. showed in vitro that the immunomodulatory effects of GFs involve VEGF secretion [21]. We showed here that VEGF, FGF7, and EGF were overexpressed earlier in GF-treated skin than in MSC-treated skin. These molecular events may contribute to the temporal difference in the effects of GF and MSC treatment.

This work is the first to demonstrate that wound healing is significantly accelerated by local injection of GFs, compared with MSC treatment. This effect is temporally associated with ECM remodeling, growth factor production, and macrophage polarization.

Using BM-MSC-derived conditioned medium previous report demonstrated that BM-MSC enhances wound healing through paracrine pathways and the growth factors and cytokines released together to modulate the local environment, affecting the proliferation, migration, differentiation, and functional recovery of resident cells [37]. The mechanism of GF therapeutic effect on wound healing such as MSC therapy involved inflammatory modulation associated to a switch of macrophages to an M2-like phenotype and an ECM remodeling is reinforced by previous observations where GF secretion factors inhibited dendritic cell differentiation [21].

The remodeling efficiency of GF has been described in treatment of arterial aneurisms in rabbit [23]. We have showed in Fig. 1 that MSC and GF expressed some growth factors and mediators implicated in anti-inflammatory response, angiogenesis, and remodeling. As compared to MSC, GF overexpressed fibroblast activation protein α and S100A4 implicated in fibroblast activation and TGF-β2, essential for hair follicle morphogenesis and regeneration. More particularly, the injected GF overexpressed about 26-fold noggin. Recently reported that the overexpressing noggin in microenvironment display continuous propagation
of hair regenerative waves and highly simplified patterns of hair cycle domains. In addition, bursts of noggin expression in the stem cell niche activated stem cells to proliferate for epithelial renewal [41]. In this way we might hypothesize here that GF by their overexpressing growth factors, which interact with microenvironment healing process and their longer persistence in wound tissue, also previously observed [23] compared to that of bone marrow-derived MSCs contributes to and accelerates tissue regeneration.

These findings indicate that GFs are a still more attractive target than the reference MSCs for regenerative medicine, for they are much easier to collect, can grow in culture, and promote cutaneous wound healing in irradiation burn lesions.

**Funding Statement**

This work was financially supported by grants from INSERM, Paris Descartes University, Ligue contre le Cancer, Association pour la Recherche sur le Cancer, Big (ANR-09-EBIO-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.

**Author Disclosure Statement**

A. Lafont, J.J. Lataillade, and B. Coulomb are cofounders of the startup ScarCell Therapeutics. The other authors have no conflicts of interest to report.

**References**


Address correspondence to:
Christine Linard, PhD
Institut de Radioprotection et de Sûreté Nucléaire
B.P. n 17
Fontenay-aux-Roses F-92262
France

E-mail: christine.linard@irsn.fr

Received for publication October 10, 2014
Accepted after revision January 5, 2015
Prepublished on Liebert Instant Online January 13, 2015